about
Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Trigger-Responsive Gene Transporters for Anticancer Therapy.The TMSB4 Pseudogene LncRNA Functions as a Competing Endogenous RNA to Promote Cartilage Degradation in Human Osteoarthritis.Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.Synthetic Nucleic Acid Analogues in Gene Therapy: An Update for Peptide-Oligonucleotide Conjugates.Bioconjugation of Small Molecules to RNA Impedes Its Recognition by Toll-Like Receptor 7.Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.Zinc Ion-Dependent Peptide Nucleic Acid-Based Artificial Enzyme that Cleaves RNA-Bulge Size and Sequence Dependence.Versatile Method for the Site-Specific Modification of DNA with Boron Clusters: Anti-Epidermal Growth Factor Receptor (EGFR) Antisense Oligonucleotide Case.2'β-Fluoro-Tricyclo Nucleic Acids (2'F-tc-ANA): Thermal Duplex Stability, Structural Studies, and RNase H Activation.In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library.Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo.Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice.
P2860
Q30354652-64586C06-B066-4817-9072-A81CDD11CA42Q33738954-0F1C2E1B-595E-4A77-9DFC-2EFFADEB178CQ33837834-13903592-6D38-47C9-AF17-62C49BB78C13Q37418494-1803A321-1C3A-4C22-9B4A-B8EA115A5193Q38288126-4A0D01A6-52A7-4433-9233-6D0BA9C66550Q38734734-E2DFD72F-1CC7-4225-9B09-764D77460C73Q39373677-12C05A01-5087-4150-9326-EC968FBA496CQ40258598-1D527CC8-06C4-41ED-9DFD-0D62AE66C674Q45869092-F4072A8D-C3B8-4148-8720-59B43AD0D7B9Q47177698-B6EB6986-DAB9-4E8D-ADBC-7E718F3A2486Q47651762-6A3931E4-A760-4D61-B760-DB071C80D202Q48182856-34F53062-892E-4ED3-8C7B-2DD77AFF132AQ49196378-D16B1DD0-9ACA-47AF-A8AA-63A19A44FBE3Q52581725-8F1281E4-1DC6-4ED8-B9BA-5B57DE884C7AQ52659503-60D984BE-A2B3-4335-BECB-43861D73A6FFQ55036897-CD0BC1D4-F9E5-4972-94AD-5D994B162DD3Q55424836-790699FD-D165-4307-8FB1-BFEBD5CA5EEA
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Therapeutic nucleic acids: current clinical status.
@en
type
label
Therapeutic nucleic acids: current clinical status.
@en
prefLabel
Therapeutic nucleic acids: current clinical status.
@en
P2860
P356
P1476
Therapeutic nucleic acids: current clinical status
@en
P2093
Nithya Jaideep Gogtay
P2860
P304
P356
10.1111/BCP.12987
P407
P577
2016-06-03T00:00:00Z